BioTime forms new subsidiary, OrthoCyte, to develop new therapeutic based stem cell technology
BioTime, Inc. announced that it has organized a new subsidiary, OrthoCyte Corporation, for the purpose of developing novel therapeutics based on stem cell technology for the treatment of injuries and disorders affecting the musculoskeletal system, including therapeutics that would regenerate bone, cartilage, tendons and ligaments.
[Read the full article here]Related News:
BioTime Sets Up OrthoCyte Subsidiary for Stem Cell Based Orthopedic Products
Biotime's new subsidiary to focus on clinical development and marketing therapeutic stem cell products in China
BioTime Subsidiary Inks Stem Cell Distribution Deal